WO1992018506A1 - Novel immunosuppressant agent from streptomyces braegensis - Google Patents

Novel immunosuppressant agent from streptomyces braegensis Download PDF

Info

Publication number
WO1992018506A1
WO1992018506A1 PCT/US1992/002324 US9202324W WO9218506A1 WO 1992018506 A1 WO1992018506 A1 WO 1992018506A1 US 9202324 W US9202324 W US 9202324W WO 9218506 A1 WO9218506 A1 WO 9218506A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
medium
gray
agar
Prior art date
Application number
PCT/US1992/002324
Other languages
French (fr)
Inventor
Walter P. Cullen
Mark A. Guadliana
Liang H. Huang
Keiji Kaneda
Nakao Kojima
Yasuhiro Kojima
Gloria J. Kostek
Satoshi Nishiyama
Yuji Yamaguchi
Original Assignee
Pfizer, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Inc. filed Critical Pfizer, Inc.
Priority to US08/129,159 priority Critical patent/US5494820A/en
Publication of WO1992018506A1 publication Critical patent/WO1992018506A1/en
Priority to FI934447A priority patent/FI934447A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Definitions

  • This invention relates to a new macrocyclic lactone immunosuppressant agent, a process for its production and its use in a human host for treatment of autoimmune diseases and/or prevention of organ transplant rejections.
  • This application is a continuation of United States application 683,639 first filed on April 11, 1991. Priority is hereby claimed to that application.
  • the United States Food and Drug Administration licensed cyclosporin, an anti-rejection drug that revolutionized the field of organ transplant surgery. The drug acts by inhibiting the body's immune system from mobilizing its vast arsenal of natural protecting agents to reject the transplant's foreign protein.
  • the compound of the formula I may be referred to as "Cg- desoxo-FK-520" because it differs from FK-520 in lacking an oxo group at the C 9 position.
  • Cg- desoxo-FK-520 the compound of the formula I may be referred to as "Cg- desoxo-FK-520" because it differs from FK-520 in lacking an oxo group at the C 9 position.
  • its stereochemistry is expected to be as shown in the following formula
  • the present invention also relates to a process for preparing the compound of the formula I comprising fermenting a compound of the formula I producing strain of bacteria (e.g. , a Streptomvces strain such as Streptomyces brae ⁇ ensis subsp. pulcherrimus Huang subsp. nov.) in an aqueous nutrient medium containing an assimilable carbon source and an assimilable nitrogen source, said fermentation being conducted preferably at a pH between about 4.0 and about 8.0, and extracting the compound of the formula I from the medium, preferably at a pH of about 4.0 to about 8.0.
  • the present invention also relates to a pharmaceutical composition containing an amount of the compound of the formula I effective in treating autoimmune disease (e.g. rheumatoid arthritis) or preventing organ transplant rejection in a mammal (e.g. a human) in combination with a pharmaceutically acceptable carrier.
  • autoimmune disease e.g. rheumatoid arthritis
  • the resent invention also relates to a method of treating a mammal (e.g. a human) to prevent transplantation rejection or treating an autoimmune disease (e.g. rheumatoid arthritis) in a mammal (e.g. a human) comprising administering to said mammal a therapeutically effective amount of the compound of the formula I.
  • a mammal e.g. a human
  • an autoimmune disease e.g. rheumatoid arthritis
  • the present invention is directed to a biologically pure culture having the characteristics of Streptomyces braegensis subsp. pulcherrimus Huang subsp. nov., ATCC 55150, and ATCC 55150 per se, as well as mutants and transformants of any of the foregoing capable of producing the compounds of the formula I, including any such culture in freeze-dried form.
  • Such a culture is capable of producing the compound of the formula I in a recoverable quantity upon fermentation in an aqueous nutrient medium comprising assimilable sources of carbon and nitrogen.
  • Figure 2 is the carbon NMR spectrum in CDC1 3 of C j - desoxo-FK-520.
  • the compound of the formula I can be produced by culturing a compound of the formula I producing strain of bacteria in an aqueous nutrient medium containing sources of assimilable carbon and nitrogen, preferably under submerged aerobic conditions (e.g. shaking culture, submerged culture, etc.).
  • the aqueous medium is preferably maintained at a pH of about 4.0 to about 8.0 throughout the fermentation process. A higher pH may lead to loss of product.
  • the desired pH may be maintained by the use of appropriate buffering agents.
  • a preferred culture for producing the compound of the formula I is designated Streptomyces braegensis subsp. pulcherrimus Huang subsp. nov. , and has been deposited in
  • the cultures were found to produce narrow hyphae of the Actinomycetales, an unfragmented substrate mycelium, and an aerial mycelium on which spore chains are produced.
  • the results of whole-cell analysis further indicates their belonging to the genus Streptomyces.
  • culture N927-101 and culture N927-101SC50 were planted from a slant into ATCC #172 broth and grown for four days at 28°C on a shaker. It was then centrifuged for 20 minutes, washed three times with sterile water and planted on media commonly used for identification of members of the Actinomycetales. The cultures were incubated at 28°C and the results were read at varying times but most commonly were taken at 14 days. The colors were described in common terminology, but exact colors were determined by comparisons with color chips from the Color Harmony Manual, fourth edition. The methods of whole-cell amino acid and sugar analyses are those described in B. Becker et al. , Appl. Microbiol.. 12. 421-423 (1964); and in M.P.
  • Glycerol-Asparagine Agar - (ISP #5 medium, Difco).
  • Peptone-Yeast Extract Iron Agar - (ISP #6 medium, Difco) .
  • Yeast Extract-Malt Extract Agar - Growth good; white, pale gray, pale pink-gray to pink-gray (near gray series 3 dc, 5 dc, 5 fe) ; raised; smooth, granular to wrinkled; aerial
  • Inorganic Salts-Starch Agar - Growth moderate to good; white, pale gray, gray to pink-gray (near gray series 3 dc, 3 fe, 5 fe) ; raised, smooth to wrinkled, aerial mycelium
  • Emerson's Agar - Growth good tan to pink (near 3 gc, 5 ea) ; raised, slightly wrinkled, no aerial mycelium; reverse brown (3 ie) ; soluble pigment yellowish brown (3 lc) .
  • Starch Agar - Growth moderate to good; white, pale gray, gray, brown to dark brown (4 ie, 4 nl, near gray series 3 dc, 3 fe) ; moderately raised, smooth to granular; aerial mycelium same as surface; reverse brown to dark brown (4 lg f 4 li) ; soluble pigment yellowish (2 lc) .
  • Morphological Properties The morphological observations were made on oatmeal agar after 15 days of incubation: spore mass in Gray color-series; spore chains in Section Spirales, tightly coiled or slightly open or coiled into an irregular mass, of small diameter (3 - 4 ⁇ m) , 3 - 8 turns per spore chain, may aggregate into a hygroscopic mass, 10 to 50 spores per spore chain; sporophores onopodially branched; spores short-rod shaped to rod shaped, sometimes globose, oval to elliptical, straight, but sometimes slightly curved, often with both ends not parallel to each other, 0.9 - 1.8 x 0.8 - 1.1 ⁇ m or 0.9 - 1.2 ⁇ m diam.; smooth to warty with a rugose surface, as revealed by scanning electron microscopy.
  • the whole-cell hydrolysates contained LL-diaminopimelic acid and galactose.
  • the culture N927-101SC50 is characterized by the gray spores in mass, the negative melanin reaction, the spiral spore chains, and the smooth to warty spores.
  • the whole cell hydrolysates indicate the presence of LL-diaminopimelic acid and galactose. Glucose, fructose, inositol, mannitol, raffinose, sucrose, and xylose were utilized; but arabinose and rhamnose were not utilized. Therefore, the culture belongs to the genus Streptomyces.
  • the parent culture N927-101 resembles culture N927- 101SC50 in all of the biochemical properties and temperature range except for minor differences in culture characteristics.
  • culture N927-101 produced dark purple rather than yellow to dark brown colony reverse and purple rather than no soluble pigment. It sporulated better than N927-101SC50 on inorganic salts-starch agar, starch agar, and gelatin agar, but worse on nutrient agar.
  • culture N927-101SC50 which is a natural isolate of culture N927-101, is the same as culture N927-101.
  • Culture N927-101SC50 is similar to S_. niqrescens in most of the biochemical properties except that the former, but not the latter, produced hydrogen sulfide and showed a better growth on cellulose broth. S. niqrescens. unlike culture N927-101SC50, showed no distinct soluble pigment and no distinct pigment on colony reverse. The colors of colony reverse ranged from yellow, yellow-gray, and gray to sometimes black.
  • Culture N927-101SC50 is similar to S_. brae ensis subsp. iaponicus in almost all of the biochemical properties except for its ability to produce hydrogen sulfide. Generally, S_. braeqensis subsp. iaponicus did not produce distinct soluble pigment. Its colony reverse varied from yellow, gray-brown, and gray-yellow-brown to dark brown. Culture N927-101SC50 has the same biochemical properties as S. braegensis except for its ability to produce hydrogen sulfide and better growth in cellulose broth.
  • the colony reverse of the latter was pale pink, reddish pink, and reddish on glucose-asparagine agar, Bennett's agar, and starch agar, respectively; but on these three media the former had a pink-gray to brown colony reverse.
  • yeast extract-malt extract agar, inorganic salts-starch agar and casein agar the former had a purple colony reverse; but the latter had a yellow-brown, pale gray to brown, and pale yellowish colony reverse, respectively.
  • Culture N927-101SC50 produced pink-gray but not pale yellow- brown soluble pigment on oatmeal agar, and yellow brown to pink but not cream to yellow-brown soluble pigment on inorganic salts-starch agar.
  • the culture N927-101SC50 represents a new subspecies of S. braegensis and is designated Streptomyces braegensis subsp. pulcherrimus Huang subsp. nov.
  • the subspecific epithet (L. adj., pulcherrimus, prettiest) refers to the beauty of a purple pigment produced on some solid media and in ATCC 172 broth. It has been deposited at the American Type Culture Collection under the accession number 55150.
  • the Streptomyces culture used to produce the compound of formula I is preferably grown at a temperature from about 20 ⁇ C to about 40 ⁇ C more preferably from about 2 ⁇ C to about 36°C, under submerged conditions with agitation and aeration in a medium consisting of a carbon source, a nitrogen source, one or more mineral salts containing trace elements such as iron, cobalt, copper, zinc etc., and one or more buffering agents.
  • the compound can be recovered by extracting the whole broth with an organic solvent (e.g., n-butanol, methyl isobutyl ketone, ethyl acetate or chloroform) , preferably at a pH of about 4.0 to about 8.0.
  • an organic solvent e.g., acetone or methanol
  • the solvent is concentrated to a thin syrup, triturated with an organic solvent (e.g., heptane) and then chromatographed (e.g., on silica gel) to obtain the pure compound.
  • the preferred sources of carbon in the nutrient medium are carbohydrates such as glucose, xylose, galactose, glycerin, starch, dextrin, maltose, rhamnose, raffinose, arabinose, mannose, and salicin.
  • Other sources which may be included are corn steep liquor, grain solubles, fish meal and cotton seed meal.
  • the preferred sources of nitrogen are yeast extract, meat extract, fish meal peptone, gluten meal, cottonseed meal, soybean meal and other vegetable meals (partially or totally defatted), casein hydrolysates, yeast hydrolysates, corn steep liquor, dried yeast, wheat germ, feather meal, peanut powder, distillers solubles as well as inorganic and organic nitrogen compounds such as ammonium salts (e.g. ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea and amino acids (e.g., casa ino acids).
  • ammonium salts e.g. ammoni
  • the preferred buffering agents are calcium carbonate or phosphates.
  • Other suitable buffering agents include morpholinoethanesulfonic acid (MES) and morpholinopropanesulfonic acid (MPS) .
  • MES morpholinoethanesulfonic acid
  • MPS morpholinopropanesulfonic acid
  • Various nutrient materials may be used which inherently possess buffering properties.
  • there may be added to the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, iron salts, zinc salts, cobalt salts, and the like.
  • a defoaming agent such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone may be added.
  • Submerged aerobic cultural conditions are preferred for producing large amounts of the compound of the formula I.
  • a shaking or surface culture in a flask or bottle is employed.
  • a vegetative inoculum of the organism by inoculating a relatively small quantity of culture medium with spores of mycelia of the organism produced in a "slant" and culturing said inoculated medium, also called the “seed medium”, and then to transfer the cultured vegetative inoculum aseptically to large tanks.
  • the fermentation medium, in which the vegetative inoculum is produced may be substantially the same as or different from the medium utilized for the production of the compound of the formula I and is generally autoclaved to sterilize the medium prior to inoculation.
  • the pH of the medium is generally adjusted to below 8.0 prior to the autoclaving step by suitable addition of an acid or base, preferably in the form of a buffering solution.
  • Agitation and aeration of the culture mixture may be accomplished in a variety of ways. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermentor by various pumping equipment or by the passage of sterile air through the medium. Aeration may be effected by passing sterile air through the fermentation mixture.
  • the fermentation is usually conducted at a temperature between about 20°C and about 40°C, preferably about 24°C to about 36 ⁇ C, for a period of about 50 hours to about 150 hours, which may be varied according to fermentation conditions and scales.
  • the production cultures are incubated for about 96 hours at 27°C on a rotary shaker operating at 220 rpm, wherein the pH of the fermentation medium is preferably maintained at a pH of about 4.0 to about 8.0, more preferably about 6.0 to about 8.0, to harvest.
  • Culturing/production media that may be used for carrying out the fermentation include the following: Medium A: glycerol, corn starch, cerelose, cotton seed meal, torula yeast, corn steep liquor, calcium carbonate and cobalt chloride, in preferred weight percentages of the fermentation medium, respectively, of: 1.0%, 1.0%, 0.5%, 1.0%, 0.5%, 0.5%, 0.2%, and 0.0005% and 0.2% (volume/volume) of an antifoam agent such as P-2000 (Dow Corning (Trademark) ) .
  • the pH of this medium is generally adjusted to about 6.3 to about 6.5 prior to autoclaving and inoculation.
  • Medium B corn starch, corn steep liquor, torula yeast, magnesium sulfate, potassium dibasic phosphate, cobalt chloride and calcium carbonate, in preferred weight percentages of the fermentation medium, respectively, of: 4.5%, 1.0%, 1.0%, 0.01%, 0.01% and 0.0001%, and 0.2% (volume/volume) of an antifoam agent such as P-2000 (Dow Corning (trademark)).
  • the pH of this medium is generally adjusted to about 7.0 to about 7.2 prior to autoclaving and inoculation.
  • Medium C cerelose, soybean meal, ammonium sulfate, potassium dibasic phosphate, calcium carbonate, NZ a ine YTT (Sheffield (trademark)) and cobalt chloride in preferred weight percentages of the fermentation medium, respectively, of: 2.0%, 3.0%, 0.5%, 0.5%, 0.3%, 0.5% and 0.0005% and 0.2% (volume/volume) of an antifoam agent such as P-2000 (Dow Corning (trademark)) .
  • the pH of this medium is generally adjusted to about 7.0 to about 7.2 prior to autoclaving and inoculation.
  • the produced compound of the formula I can be recovered from the culture medium by conventional means which are commonly used for the recovery of the other known biologically active substances.
  • the compound of the formula I produced is found in the cultured mycelium and filtrate, and accordingly can be isolated and purified from the mycelium and the filtrate.
  • the mycelium can be separated, by filtering or centrifuging the cultured broth.
  • the mycelium can then be extracted with a conventional solvent, such as methanol or acetone, separated and concentrated.
  • a conventional resin e.g., anion or cation exchange resin, non-ionic adsorption resin, etc.
  • a conventional adsorbent e.g., activated charcoal, silic acid, silica gel, cellulose, florisil, alumina, etc.
  • crystallization, and recrystallization are then performed to recover the desired compound.
  • inoculum is prepared by scraping vegetative cells from slant.s or Roux bottles inoculated with the N927-101 culture.
  • a solid medium suitable for initial growth on slants and Roux bottles is ATCC medium 172 described below:
  • Vegetative cells from slants are used to inoculate either shake flasks or inoculum tanks; or alternatively the inoculu tanks are inoculated from shake flasks. In shake flasks, growth will generally have reached its maximum in 48 to 96 hours whereas in the inoculum tanks growth will usually be at the most favorable period in 72 to 120 hours.
  • a fermenter is inoculated with vegetative broth from the inoculum flasks or tank under completely aseptic conditions and fermented for a period of 72 to 120 hours. Aeration is maintained in the shake flask by agitation on a shaker or in tanks by forcing sterile air through a sparger at the rate of 1/2 to 2 volume of air per volume of broth per minute.
  • the speed of agitation depends upon the type of agitator employed; a shake flask is usually run at 150 to 200 cycles, per minute (cpm) and a fermenter at 300 to 1700 revolutions per minute (rpm) . Sterility must be maintained at all times.
  • the temperature is regulated between 24°C and 36°C. Foaming during the fermentation can be controlled with sterile antifoams such as refined soybean oil, or other suitable antifoaming agents added to the makeup or to the fermenter aseptically as needed after inoculation.
  • Shake flasks are prepared using one of the following media:
  • P-2000 is added as an antifoaming agent to the jar fermenters only, then the vessels are sealed and sterilized at 120°C and 1.06 kg/cm 2 for 60 to 90 minutes.
  • the jars are inoculated with one (about 3% inoculum) flask, fermented for 72 to 120 hours at 27 ⁇ C and stirred at 1700 rpm with an air rate of one volume of air per volume of liquid per minute.
  • the shake flasks (Fernbachs) are run at 150 ⁇ 200 cpm on a shaker at 28°C and fermented for 72 to 120 hours.
  • the fermenters are stopped and the contents extracted twice with one third to one half volume of a solvent such as methyl isobutyl ketone or n-butanol.
  • a solvent such as methyl isobutyl ketone or n-butanol.
  • the solvent layer is separated by aspiration or centrifugation, sparkled, and concentrated in vacuo to a viscous oil.
  • the bioactivity of the broth and subsequent recovery streams can be followed by HPLC or by using a strain of a filamentous fungi, e.g., Byssochlamys fulva.
  • the components in the broth and recovery streams can also be visualized by chromatography on Analtech silica gel FG (trademark) plates using neat ethyl acetate or chlorofor -methanol 10:1 as the eluant.
  • the developed plates are viewed under ultraviolet light at 254 nm or are sprayed with vanillin reagent (e.g.. 3 g vanillin in 75 ml of ethanol and 25 ml 85% phosphoric acid) and heated to 80°C.
  • vanillin reagent e.g. 3 g vanillin in 75 ml of ethanol and 25 ml 85% phosphoric acid
  • Extracts of the broth may be run in a Waters (trademark) analytical HPLC using a Zorbax CN (trademark) column
  • the shake flask inoculum is fermented for 2 to 4 days at 28°C, and then used to inoculate a 50-gallon fermenter containing 25 gallons of production medium.
  • the broth is harvested after running 3 to 5 days.s
  • the whole broth is extracted with 1/3 volume of methyl isobutyl ketone (MIBK) at natural pH, separated on an Alpha De Laval (trademark) separator and the solvent phase concentrated in vacuo to an oil.
  • MIBK methyl isobutyl ketone
  • the term natural pH refers to the pH of the fermentation when stopped, or, if the pH is controlled, the pH at which the fermentation was run or maintained.
  • the oil thus obtained may be processed as described below in Example 1.
  • a 100-gallon charge of compound of formula I seed medium is inoculated by side arm flask, run approximately 48 hours, then pumped aseptically into 1000 gallons of production medium.
  • the compound of the formula I inhibits the rotamase activity of human FK-binding protein.
  • Functional biological activity in a human mixed lymphocyte reaction (MLR) may be demonstrated by standard procedures well known to those skilled in the art.
  • the immunosuppressant effect of the compound of the formula I may also be demonstrated by the following assay which measures the proliferation of mouse T lymphocytes stimulated with the combination of ionomycin plus PMA (phorbol myristate acetate) . A positive sample in this assay will inhibit T-cell proliferation, as indicated by reduced tritiated thy idine uptake.
  • Spleens from C57BI/6 mice are taken under sterile conditions and gently dissociated in ice-cold RPMI 1640 (trademark) culture medium (GIBCO (trademark) ) supplemented with 10% heat-inactivated fetal calf serum (GIBCO (trademark) ) .
  • Cells are pelleted by centrifugation at 1500 rpm for 8 minutes. Contaminating red cells are removed by treating the pellet with ammonium chloride lysing buffer (GIBCO (trademark) ) for 2 minutes at 4 ⁇ C. Cold medium is added and cells are again centrifuged at 1500 rpm for 8 minutes.
  • T lymphocytes are then isolated by separation of the cell suspension on nylon wool columns as follows: Nylon wool columns are prepared by packing approximately 4 grams of washed and dried nylon wool into 20 ml plastic syringes. The columns are sterilized by autoclaving at 120 ⁇ C for 30 minutes. Nylon wool columns are wetted with warm (37°C) culture medium and rinsed with the same medium. Washed spleen cells resuspended in warm medium are slowly applied to the nylon wool. The columns are then incubated in an upright position at 37°C for 1 hour. Non-adherent T lymphocytes are eluted from the columns with warn culture medium and the cell suspensions are spun as above.
  • Purified T lymphocytes are resuspended at 10 6 cells/ml in complete culture medium composed of RPMI 1640 (trademark) medium with 10% heat-inactivated fetal calf serum, 100 mM glutamine, lmM sodium pyruvate, 20 ⁇ m 2-mercaptoethanol and 50 ⁇ g/ l gentamicin. Ionomycin is added at 250 ng/ml and PMA at 10 ng/ml. The cell suspension is immediately distributed into 96-well flat-bottom microculture plates (Costar (trademark)) at 100 ⁇ l/well. Control (cyclosporin) medium or sample to be tested are then added in triplicate wells at 10 ⁇ l/well.
  • the culture plates are then incubated at 37 ⁇ C in a humidified atmosphere of 5% C0 2 -95% air for 44 hours.
  • the proliferation of T lymphocytes is assessed by measurement of tritiated thymidine incorporation.
  • the cells are pulse-labelled with 2 Ci/well of tritiated thymidine (New England Nuclear (trademark) ) .
  • cultures are harvested on glass fiber filters using a multiple sample harvester. Radioactivity of filter discs corresponding to individual wells is measured by standard liquid scintillation counting method (Beta plate counter) .
  • the compound of the formula I has immunosuppressive activity and is therefore useful for the treatment and prevention, of the transplantation rejection of organs or tissues such as heart, kidney, liver, medulla ossium, skin, etc., graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis and type I diabetes.
  • the compound also has antimicrobial activity and is useful in treating infectious diseases caused by pathogenic filamentus fungal organisms.
  • compositions of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semi-solid or liquid form, which contains a compound of the formula I as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications.
  • the active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
  • the carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semi-solid, or liquid form, and in -23- addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.
  • a daily dose (calculated on the basis of a 70 kg man) of about 0.01 to about 1000 mg, preferably about 0.1 to about 500 mg and more preferably about 0.5 to about 100 mg of the active ingredient is generally given for treating transplantation rejection or the diseases referred to above, and an average single dose of about 0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg or 500 mg is generally administered.
  • a daily dose (calculated on the basis of a 70 kg man) of about 0.01 to about 1000 mg, preferably about 0.1 to about 500 mg and more preferably about 0.5 to about 100 mg of the active ingredient is generally given for treating transplantation rejection or the diseases referred to above, and an average single dose of about 0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg or 500 mg is generally administered.
  • the following examples are given for the purpose of illustrating the present invention and should not be construed as being limitations on its scope.
  • Example 1 Fermentation of N927-101 The organism N927-101 was isolated from a soil sample collected in Misumitown, Yamaguchi Prefecture, Japan. A. Microtiter Fermentation
  • a sample of N927-101 colony on an agar-plate was inoculated into a seed medium W (2.5 ml) containing glucose (1 g) , dextrin, polypeptone (5 g/1), yeast extract (5 g/1), beef extract (3 g/1) and CaC0 3 (4 g/1) in a 24-well microtiter plate and cultured at 28°C for 3 days on a rotary shaker with 7-cm throw at 200 rpm.
  • the seed culture (0.15- 0.3 ml) thus obtained was inoculated to a production medium (3 ml) containing glucose (10 g/1), corn starch (20 (g/1), NZ amine type-A (5 g/1) , yeast extract 5 (g/1) , wheat embryo (5 g/1), COCl 2 »H 2 0 (0.001 (g/1) and CaC0 3 (4 g/1) in a 24-well microtiter plate and cultured under the same conditions as the above seed culture except that the fermentation was 4 days.
  • the fermentation broth thus obtained was applied to a TLC (thin layer chromatography) plate (Kieselgel ⁇ OF ⁇ , E. Merck (trademark) 20x20 cm) and developed by CHC1 3 : CH 3 OH (9:1). After the solvent was removed, the TLC plate was placed in a bioplate (28x44 cm) and overlayed by 300 ml of malt yeast agar (malt extract 20 g, yeast extract 4 g, agar 20 g in 1,000 ml) seeded with Byssochlamys fulva. The bioplate was incubated at 28 ⁇ C for 48 hours. At least two compounds were detected as the inhibition zones against the test organism with R f values of 0.30 and 0.55. B.
  • TLC thin layer chromatography
  • Flask Fermentation In order to determine whether the compounds produced by the N927-101 colony where the same as known compounds, flask fermentation was carried out. A seed culture (100 ml) inoculated with 0.5 ml of frozen seed-culture from the microtiter fermentation was fermented as described above and then 5 ml were used to prepare 100 ml of a main culture which was fermented as described above. 150 ml of the resulting fermentation broth was extracted with 100 ml of ethyl acetate (EtOAc) . The EtOAc solution was concentrated to dryness. The residue was dissolved in 2 ml of acetone and submitted to TLC-bioautography.
  • EtOAc ethyl acetate
  • a first seed culture was prepared by inoculating 100 ml of medium with 5 ml of frozen seed culture from the shake-flask fermentation.
  • the medium comprised water, glucose (20 g/1) , polypeptone (5 g/1) , yeast extract (5 g/1), beef extract (3 g/1), wheat gluten (5 g/1), blood meal (3 g/1) , and CaC0 3 (4 g/1) .
  • the culture was maintained at 28 ⁇ C for four days with rotation at 200 rpm.
  • Second seed cultures were prepared by inoculating 150 ml of WGB medium with 7.5 ml of the fermented first seed culture. The culture was maintained at 28°C for three days with rotation at 200 rpm and aeration at 1.0 volume/volume/minute.
  • Main cultures were prepared in five 6-liter mini-jars by inoculating 3 liters of medium in each jar with 150 ml of the second seed culture.
  • the medium comprised glucose (10 g/1) , dextrin (20 g/1) , wheat gluten (10 g/1) , corn steep liquor (5 g/1), polypeptone (1 g/1), (NH 4 ) 2 S0 4 (1 g/1), CaC0 3 (4 g/1) and COC1 2 .6H 2 0 (0.001 g/1).
  • the whole mini-jar fermentation broth (15 1) was freeze-dried and the solid (397 g) was extracted with two 5- liter portions of 70% aqueous acetone and concentrated to 2.5 1 of aqueous suspension.
  • the suspension was extracted with two 2-liter portions of methyl isobutyl ketone and the combined extract was concentrated to oily residue.
  • a small amount of ether (100 ml) was added to the oily residue to give a precipitate. After collecting the precipitate (2.8 g), the ether solution was concentrated and 100 ml of n-hexane was added to yield 1.7 g of gum-solid.
  • the 2.8 and 1.7 g gum solids were combined and applied to a 120 g fine mesh silica gel column which was developed with 1 L of 3:1 hexanes/ethyl acetate, followed by 1 L of 2:1 hexanes/ethyl acetate, 1 L of 1:1 hexanes/ethyl acetate, 1 L of 2:1 ethyl acetate/hexanes and finally by 2 L of ethyl acetate to yield 25 mg of FK-520 and 125 mg of a mixture of FK-520 and a novel compound.
  • Example 2 Large Scale Flask Fermentation Shake flasks containing 80 ml of ATCC 172 medium were inoculated and fermented for 3 to 4 days at 28°C, then 10 ml was used to inoculate a 2.8 liter Fernbach flask containing one liter of ATCC 172 medium. The fermenter, after running 3 to 5 days, was harvested.
  • MIBK methyl isobutyl ketone
  • the column was developed with 1 L of 1:1 ethyl acetate/hexanes, followed by 1 L of 2:1 ethyl acetate/hexanes, 1 L of 4:1 ethyl acetate/hexanes and finally by 1.5 L of ethyl acetate to yield 290 mg of a yellow oil.
  • This mixture was then chromatographed on a second fine mesh silica gel column which was pre-equilibrated with chloroform and developed with 200 ml of chloroform, followed by 500 ml of chloroform with 1% methanol and then with 500 ml of chloroform with 2% methanol to yield 125 mg of an oil.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A compound of formula (I) is a novel immunosuppressant agent prepared by fermenting Steptomyces braegensis subsp. pulcherrimus, ATCC 55150, or another compound of formula (I) producing strain and extracting the compound of formula (I) from the fermentation medium. The compound is useful in treating transplant rejection and autoimmune diseases.

Description

-i- NOVEL IMMUNOSUPPRESSANT AGENT
FROM STREPTOMYCES BRAEGENSIS Background of the Invention This invention relates to a new macrocyclic lactone immunosuppressant agent, a process for its production and its use in a human host for treatment of autoimmune diseases and/or prevention of organ transplant rejections. This application is a continuation of United States application 683,639 first filed on April 11, 1991. Priority is hereby claimed to that application. In 1983, the United States Food and Drug Administration licensed cyclosporin, an anti-rejection drug that revolutionized the field of organ transplant surgery. The drug acts by inhibiting the body's immune system from mobilizing its vast arsenal of natural protecting agents to reject the transplant's foreign protein. Although cyclosporin is effective in fighting transplantation rejection, it suffers drawbacks in causing kidney failure, liver damage and ulcers which in many cases can be very severe. Newer, safer drugs exhibiting less side effects are constantly being searched for. European Patent Publication No. 0184162 of Fujisawa Pharmaceutical Co., Ltd., describes the macrolide immunosuppressants FK-506 and FK-520. The latter is produced by S_. hyσroscopicus subsp. vakushi aensis No. 7238. Other immunosuppressants are described in European Patent Application Publication Numbers 0323042, 0323865, 0356399 of Fisons pic, Merck & Co. Inc., and Sandoz, respectively.
Summary of the Invention The present invention relates to a new immuno- suppressant of the formula
SUBSTITUTE SHEET
Figure imgf000004_0001
The compound of the formula I may be referred to as "Cg- desoxo-FK-520" because it differs from FK-520 in lacking an oxo group at the C9 position. In view of the compound's similarity to FK-520 its stereochemistry is expected to be as shown in the following formula
Figure imgf000004_0002
The present invention also relates to a process for preparing the compound of the formula I comprising fermenting a compound of the formula I producing strain of bacteria (e.g. , a Streptomvces strain such as Streptomyces braeσensis subsp. pulcherrimus Huang subsp. nov.) in an aqueous nutrient medium containing an assimilable carbon source and an assimilable nitrogen source, said fermentation being conducted preferably at a pH between about 4.0 and about 8.0, and extracting the compound of the formula I from the medium, preferably at a pH of about 4.0 to about 8.0. The present invention also relates to a pharmaceutical composition containing an amount of the compound of the formula I effective in treating autoimmune disease (e.g. rheumatoid arthritis) or preventing organ transplant rejection in a mammal (e.g. a human) in combination with a pharmaceutically acceptable carrier.
The resent invention also relates to a method of treating a mammal (e.g. a human) to prevent transplantation rejection or treating an autoimmune disease (e.g. rheumatoid arthritis) in a mammal (e.g. a human) comprising administering to said mammal a therapeutically effective amount of the compound of the formula I.
Finally, the present invention is directed to a biologically pure culture having the characteristics of Streptomyces braegensis subsp. pulcherrimus Huang subsp. nov., ATCC 55150, and ATCC 55150 per se, as well as mutants and transformants of any of the foregoing capable of producing the compounds of the formula I, including any such culture in freeze-dried form. Such a culture is capable of producing the compound of the formula I in a recoverable quantity upon fermentation in an aqueous nutrient medium comprising assimilable sources of carbon and nitrogen.
Description of the Drawinσs Figure 1 is the proton NMR spectrum in CDC13 of the compound of the formula I, C9-desoxo-FK-520.
Figure 2 is the carbon NMR spectrum in CDC13 of Cj- desoxo-FK-520.
Detailed Description of the Invention In general, the compound of the formula I can be produced by culturing a compound of the formula I producing strain of bacteria in an aqueous nutrient medium containing sources of assimilable carbon and nitrogen, preferably under submerged aerobic conditions (e.g. shaking culture, submerged culture, etc.). The aqueous medium is preferably maintained at a pH of about 4.0 to about 8.0 throughout the fermentation process. A higher pH may lead to loss of product. The desired pH may be maintained by the use of appropriate buffering agents.
A preferred culture for producing the compound of the formula I is designated Streptomyces braegensis subsp. pulcherrimus Huang subsp. nov. , and has been deposited in
The American Type Culture Collection, Rockville, Maryland under their accession number ATCC 55150.
This.. novel culture was derived from a soil sample collected in Misumitown, Yamaguchi prefecture, Japan, and identified in the culture collection of Pfizer Inc as N927- 101. Its single colony isolate is identified as N927-101- SC50. Its description and classification were provided by Dr. L. H. Huang.
The cultures were found to produce narrow hyphae of the Actinomycetales, an unfragmented substrate mycelium, and an aerial mycelium on which spore chains are produced. The results of whole-cell analysis further indicates their belonging to the genus Streptomyces.
Each of culture N927-101 and culture N927-101SC50 was planted from a slant into ATCC #172 broth and grown for four days at 28°C on a shaker. It was then centrifuged for 20 minutes, washed three times with sterile water and planted on media commonly used for identification of members of the Actinomycetales. The cultures were incubated at 28°C and the results were read at varying times but most commonly were taken at 14 days. The colors were described in common terminology, but exact colors were determined by comparisons with color chips from the Color Harmony Manual, fourth edition. The methods of whole-cell amino acid and sugar analyses are those described in B. Becker et al. , Appl. Microbiol.. 12. 421-423 (1964); and in M.P. Lechevalier, J. Lab. Clin. Med.. 71. 934-944 (1968). For comparison purposes, the type strains of Streptomyces tsukubaensis BP-927, S. hyqroscopicus subsp. yakushimaensis BP-928, S . niqrescens ATCC 23941, S. braeqensis NRRL 12567, and S. braeqensis subsp. iaponicus N617-29 were used.
Identification media used for the characterization of the cultures and references for their composition are as follows:
I. Tryptone-Yeast Extract Broth - (ISP #1 medium, Difco) . 2. Yeast Extract-Malt Extract Agar - (ISP #2 medium,
Difco) .
3. Oatmeal Agar - (ISP #3 medium, Difco).
4. Inorganic Salts-Starch Agar - (ISP #4 medium, Difco).
5. Glycerol-Asparagine Agar - (ISP #5 medium, Difco). 6. Peptone-Yeast Extract Iron Agar - (ISP #6 medium, Difco) .
7. Czapek-Sucrose Agar - S.A. Waksman, The Actinomvcetes. Vol. 2, medium no. 1, p. 328, (1961).
8. Glucose-Asparagine Agar - Ibid, medium no. 2, p. 328. 9. Bennett's Agar - Ibid, medium no. 30, p. 331.
10. Emerson's Agar - Ibid, medium no. 28, p. 331.
II. Nutrient Agar - Ibid, medium no. 14, p. 330.
12. Gordon and Smith's Tyrosine Agar - R.E. Gordon and M. M. Smith, J. Bacteriol., 69, 147-150 (1955). 13. Casein Agar - Ibid.
14. Calcium Malate Agar - S.A. Waksman, Bacteriol. Rev.. 21, 1-29 (1957).
15. Gelatin - R. E. Gordon and J. M. Mihm, J. Bacteriol.. 73. 15-27 (1957) . 16. Starch - Ibid.
17. Organic Nitrate Broth - Ibid.
18. Dextrose Nitrate Broth - S.A. Waksman, The Actinomycetes. Vol. 2, medium no. 1, p. 328 (1961), with 3 g dextrose substituted for 30 g sucrose and agar omitted. -6-
19. Potato Carrot agar - M.P. Lechevalier, £, Lab, and Clinical ____. , 7JL, 934-944 (1968), but use only 30 g potatoes, 2.5 g carrots and 20 g agar.
20. 2% Tap Water Agar. 5 21. Skim Milk - Difco.
22. Cellulose utilization - a) H. L. Jensen, Proc. Linn. Soc. N.S.W. f 55, 231-248 (1930) b) M. Levine and H. W. Schoenlein, A Compilation of 10 Culture Media, medium no. 2511 (1930) .
23. Carbohydrate Utilization - (ISP #9 medium, Difco).
24. Temperature Range - ATCC 172 medium in ATCC Media Handbook, 1st Ed., p. 10 (1984).
The cultural characteristics of culture N927-101SC50,
15 which produced higher titers of the compound of the formula I than culture N927-101, are as follows:
Yeast Extract-Malt Extract Agar - Growth good; white, pale gray, pale pink-gray to pink-gray (near gray series 3 dc, 5 dc, 5 fe) ; raised; smooth, granular to wrinkled; aerial
20 mycelium same as surface; reverse yellowish to dark brown (2 ic, 4 ni, 4 li) ; no soluble pigment.
Oatmeal Agar - Growth moderate to good; white, pale gray to gray (near gray series 3 dc, 3 fe) ; slightly raised, smooth to granular, aerial mycelium same as surface; reverse gray
25 to pink-gray (near gray series 3 fe, 5 fe, 7 ih) ; soluble pigment pink-gray (near gray series 5 dc) .
Inorganic Salts-Starch Agar - Growth moderate to good; white, pale gray, gray to pink-gray (near gray series 3 dc, 3 fe, 5 fe) ; raised, smooth to wrinkled, aerial mycelium
30 same as surface; reverse purplish black (near gray series 7 ml) ? soluble pigment yellowish brown to pink (3 gc, 6 ca) . Glycerol-Asparaqine Agar - Growth poor to moderate; white, cream, pale gray to gray (2 ca, near gray series 3 dc, 3 fe) ; appearing as isolated colonies, thin to slightly
35 raised, smooth to granular; aerial mycelium white, pale gray to gray; reverse cream to yellowish (2 ca, 2 nc, 2 pe) ; no soluble pigment. Czapek-Sucrose Agar - Growth poor to moderate, pale gray to gray (near gray series 3 dc, 3 fe, 5 ih) ; thin to slightly raised, smooth to granular, aerial mycelium same as surface; reverse colorless, pale gray to gray (near gray series 3 dc, 3 fe) ; no soluble pigment.
Glucose-Asparagine Agar - Growth moderate; yellow, gray to pink-gray (2 ic, near gray series 3 fe, 7 ih) ; appearing as isolated colonies; smooth, wrinkled to granular; aerial mycelium gray to pink-gray; reverse pink-gray (near gray series 7 ih) ; soluble pigment none to pale pink (4 ca) .
Gordon and Smith's Tyrosine Agar - Growth moderate, brown (4 le) ; slightly raised, smooth to slightly granular; aerial mycelium sparse, white to pale gray (near gray series 3 dc) ; reverse brown (3 ic, 4 lc) ; soluble pigment yellowish brown (3 nc) .
Casein Agar - Growth good; white, grayish yellow to lavender (2 gc, 4 ge) ; raised, smooth to wrinkled, aerial mycelium white; reverse yellowish to lavender (2 ga, 2 ic, 4 ge) ; soluble pigment yellowish brown (3 lc) . Bennett's Agar - Growth excellent; white, pale gray to gray (near gray series 3 dc, 3 fe) ; highly raised; smooth, slightly wrinkled to granular; aerial mycelium same as surface; reverse pink-gray to dark pink-gray (near gray series 7 ih, 7 ml) ; soluble pigment yellowish (2 ga) . Emerson's Agar - Growth good, tan to pink (near 3 gc, 5 ea) ; raised, slightly wrinkled, no aerial mycelium; reverse brown (3 ie) ; soluble pigment yellowish brown (3 lc) . Nutrient Agar - Growth moderate; white, pale pink-gray to pink-gray (near gray series 5 ic, 5 fe) ; appearing as isolated colonies, moderately raised, smooth to wrinkled; aerial mycelium same as surface; reverse yellowish to brown (2 ga, 2 ic, 4 ie) ; no soluble pigment.
Calcium Malate Agar - Growth scant, pale gray to gray (near gray series 3 dc, 3 fe) ; slightly raised, thin, smooth, aerial mycelium same as surface; reverse same as surface; no soluble pigment. Potato Carrot Agar - Growth moderate, pink-gray to dark pink-gray (near gray series 5 ih, 5 ml) , appearing as isolated colonies, slightly raised, smooth, aerial mycelium same as surface; reverse same as surface; no soluble pigment.
Tap Water Agar - Growth poor; pale gray, gray to pink-gray (near gray series 3 dc, 3 fe, 7 ih) ; thin, smooth; aerial mycelium same as surface; reverse pale gray to gray (near gray series 3 dc, 3 fe) ; no soluble pigment. Gelatin Agar - Growth moderate to good; white to brown (3 le) , but pale yellowish brown (3 gc) at edge; moderately raised; smooth, granular to slightly wrinkled; aerial mycelium white; reverse brown to dark brown (4 ie, 4 pi, 4 ni) ; no soluble pigment. Starch Agar - Growth moderate to good; white, pale gray, gray, brown to dark brown (4 ie, 4 nl, near gray series 3 dc, 3 fe) ; moderately raised, smooth to granular; aerial mycelium same as surface; reverse brown to dark brown (4 lgf 4 li) ; soluble pigment yellowish (2 lc) . Morphological Properties - The morphological observations were made on oatmeal agar after 15 days of incubation: spore mass in Gray color-series; spore chains in Section Spirales, tightly coiled or slightly open or coiled into an irregular mass, of small diameter (3 - 4 μm) , 3 - 8 turns per spore chain, may aggregate into a hygroscopic mass, 10 to 50 spores per spore chain; sporophores onopodially branched; spores short-rod shaped to rod shaped, sometimes globose, oval to elliptical, straight, but sometimes slightly curved, often with both ends not parallel to each other, 0.9 - 1.8 x 0.8 - 1.1 μm or 0.9 - 1.2 μm diam.; smooth to warty with a rugose surface, as revealed by scanning electron microscopy.
Biochemical Properties - Melanin not produced; hydrogen sulfide produced; gelatin liquefied; starch hydrolyzed; nitrate not reduced to nitrite; good growth but no decomposition on both cellulose broths; clearing but no coagulation on milk; casein digestion positive; tyrosine digestion positive; calcium malate digestion negative. Carbohydrate utilization: Glucose, fructose, inositol, annitol, raffinose, sucrose, and xylose utilized; arabinose and rhamnose not utilized.
Figure imgf000011_0001
Cell Wall Analysis - The whole-cell hydrolysates contained LL-diaminopimelic acid and galactose.
The culture N927-101SC50 is characterized by the gray spores in mass, the negative melanin reaction, the spiral spore chains, and the smooth to warty spores. The whole cell hydrolysates indicate the presence of LL-diaminopimelic acid and galactose. Glucose, fructose, inositol, mannitol, raffinose, sucrose, and xylose were utilized; but arabinose and rhamnose were not utilized. Therefore, the culture belongs to the genus Streptomyces.
The parent culture N927-101 resembles culture N927- 101SC50 in all of the biochemical properties and temperature range except for minor differences in culture characteristics. On yeast extract-malt extract agar, culture N927-101 produced dark purple rather than yellow to dark brown colony reverse and purple rather than no soluble pigment. It sporulated better than N927-101SC50 on inorganic salts-starch agar, starch agar, and gelatin agar, but worse on nutrient agar. Although the black hygroscopic patches in culture N927-101SC50 were not as obvious as in culture N927-101 at 15 days of incubation, almost all of the colonies of both cultures have turned black on the following agars after six weeks of incubation: yeast extract-malt extract agar, oatmeal agar, inorganic salts-starch agar, Czapek-sucrose agar, Bennett's agar, potato carrot agar, and tap water agar. Thus, it is concluded that culture N927- 101SC50, which is a natural isolate of culture N927-101, is the same as culture N927-101. When culture N927-101SC50 was compared with FK-506 producing culture S_. tsukubaensis BP-927 and FK-520 and FK- 523 producing culture £. hygroscopicus subsp. yakushimaensis BP-928 (available from the Fermentation Research Institute in Japan) , the differences are apparent (Table 1) . In addition, culture S_. tsukubaensis produced an orange tint of soluble pigment on yeast extract-malt extract agar, oatmeal agar, and glucose-asparagine agar; whereas S_. hygroscopicus subsp. yakushimaensis produced no distinct soluble pigment. On yeast extract-malt extract agar, and inorganic salts- starch agar, the colony reverse was brown and gray-pink, respectively, for S_. tsukubaensis. but was gray to dark gray and yellow-gray to black for S. hygroscopicus subsp. yakushimaensis. When compared with known species of Streptomyces. the culture N927-101SC50 closely resembles Streptomyces braegensis Dietz NRRL 12567 (U.S. Patent 4,404,190, Sept. 13, 1983), S_. braegensis Dietz subsp. japonicus Huang N617-29 (Ranee, M. J. et al. , J. Antibiot.. 42. 206-217 (1989)), and S. nigrescens (Sveshnikova) Pridham et al. ATCC 23941 (Shirling, E.B. and D. Gottlieb, Int. J. Syst. Bacteriol . 18_, 279-396 (1968)). These three cultures were grown for comparisons.
Culture N927-101SC50 is similar to S_. niqrescens in most of the biochemical properties except that the former, but not the latter, produced hydrogen sulfide and showed a better growth on cellulose broth. S. niqrescens. unlike culture N927-101SC50, showed no distinct soluble pigment and no distinct pigment on colony reverse. The colors of colony reverse ranged from yellow, yellow-gray, and gray to sometimes black.
Culture N927-101SC50 is similar to S_. brae ensis subsp. iaponicus in almost all of the biochemical properties except for its ability to produce hydrogen sulfide. Generally, S_. braeqensis subsp. iaponicus did not produce distinct soluble pigment. Its colony reverse varied from yellow, gray-brown, and gray-yellow-brown to dark brown. Culture N927-101SC50 has the same biochemical properties as S. braegensis except for its ability to produce hydrogen sulfide and better growth in cellulose broth. The colony reverse of the latter was pale pink, reddish pink, and reddish on glucose-asparagine agar, Bennett's agar, and starch agar, respectively; but on these three media the former had a pink-gray to brown colony reverse. On yeast extract-malt extract agar, inorganic salts-starch agar and casein agar, the former had a purple colony reverse; but the latter had a yellow-brown, pale gray to brown, and pale yellowish colony reverse, respectively. Culture N927-101SC50 produced pink-gray but not pale yellow- brown soluble pigment on oatmeal agar, and yellow brown to pink but not cream to yellow-brown soluble pigment on inorganic salts-starch agar.
On the basis of the above results, it is concluded that the culture N927-101SC50 represents a new subspecies of S. braegensis and is designated Streptomyces braegensis subsp. pulcherrimus Huang subsp. nov. The subspecific epithet (L. adj., pulcherrimus, prettiest) refers to the beauty of a purple pigment produced on some solid media and in ATCC 172 broth. It has been deposited at the American Type Culture Collection under the accession number 55150.
TABLE 1 Comparisons of N927-101SC50 with S. tsukubaensis and £ϊ. hygroscopicus subsp. yakushimaensis
Figure imgf000014_0001
The Streptomyces culture used to produce the compound of formula I (e.g., N927-101 or N927-101SC50) is preferably grown at a temperature from about 20βC to about 40βC more preferably from about 2 βC to about 36°C, under submerged conditions with agitation and aeration in a medium consisting of a carbon source, a nitrogen source, one or more mineral salts containing trace elements such as iron, cobalt, copper, zinc etc., and one or more buffering agents. The compound can be recovered by extracting the whole broth with an organic solvent (e.g., n-butanol, methyl isobutyl ketone, ethyl acetate or chloroform) , preferably at a pH of about 4.0 to about 8.0. Alternatively, after growth has been completed, the mycelium may be separated and extracted with an organic solvent (e.g., acetone or methanol) as described above, and the filtrate discarded. The solvent is concentrated to a thin syrup, triturated with an organic solvent (e.g., heptane) and then chromatographed (e.g., on silica gel) to obtain the pure compound.
The preferred sources of carbon in the nutrient medium are carbohydrates such as glucose, xylose, galactose, glycerin, starch, dextrin, maltose, rhamnose, raffinose, arabinose, mannose, and salicin. Other sources which may be included are corn steep liquor, grain solubles, fish meal and cotton seed meal. The preferred sources of nitrogen are yeast extract, meat extract, fish meal peptone, gluten meal, cottonseed meal, soybean meal and other vegetable meals (partially or totally defatted), casein hydrolysates, yeast hydrolysates, corn steep liquor, dried yeast, wheat germ, feather meal, peanut powder, distillers solubles as well as inorganic and organic nitrogen compounds such as ammonium salts (e.g. ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea and amino acids (e.g., casa ino acids).
The preferred buffering agents are calcium carbonate or phosphates. Other suitable buffering agents include morpholinoethanesulfonic acid (MES) and morpholinopropanesulfonic acid (MPS) . Various nutrient materials may be used which inherently possess buffering properties. The carbon and nitrogen sources, though advantageously employed in combination, need not be used in their pure form. Less pure materials, which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use. When desired, there may be added to the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, iron salts, zinc salts, cobalt salts, and the like. If necessary, especially when the culture medium foams, a defoaming agent, such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone may be added. Submerged aerobic cultural conditions are preferred for producing large amounts of the compound of the formula I. For the production of the compound of the formula I in small amounts, a shaking or surface culture in a flask or bottle is employed. When fermentation is carried out in large tanks, it is preferable to use the vegetative form of the organism for inoculation in the production tanks in order to avoid growth lag in the process of production of the compound of the formula I. Accordingly, it is desirable first to produce a vegetative inoculum of the organism by inoculating a relatively small quantity of culture medium with spores of mycelia of the organism produced in a "slant" and culturing said inoculated medium, also called the "seed medium", and then to transfer the cultured vegetative inoculum aseptically to large tanks. The fermentation medium, in which the vegetative inoculum is produced, may be substantially the same as or different from the medium utilized for the production of the compound of the formula I and is generally autoclaved to sterilize the medium prior to inoculation. The pH of the medium is generally adjusted to below 8.0 prior to the autoclaving step by suitable addition of an acid or base, preferably in the form of a buffering solution.
Agitation and aeration of the culture mixture may be accomplished in a variety of ways. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermentor by various pumping equipment or by the passage of sterile air through the medium. Aeration may be effected by passing sterile air through the fermentation mixture.
The fermentation is usually conducted at a temperature between about 20°C and about 40°C, preferably about 24°C to about 36βC, for a period of about 50 hours to about 150 hours, which may be varied according to fermentation conditions and scales. Preferably, the production cultures are incubated for about 96 hours at 27°C on a rotary shaker operating at 220 rpm, wherein the pH of the fermentation medium is preferably maintained at a pH of about 4.0 to about 8.0, more preferably about 6.0 to about 8.0, to harvest.
Culturing/production media that may be used for carrying out the fermentation include the following: Medium A: glycerol, corn starch, cerelose, cotton seed meal, torula yeast, corn steep liquor, calcium carbonate and cobalt chloride, in preferred weight percentages of the fermentation medium, respectively, of: 1.0%, 1.0%, 0.5%, 1.0%, 0.5%, 0.5%, 0.2%, and 0.0005% and 0.2% (volume/volume) of an antifoam agent such as P-2000 (Dow Corning (Trademark) ) . The pH of this medium is generally adjusted to about 6.3 to about 6.5 prior to autoclaving and inoculation. Medium B: corn starch, corn steep liquor, torula yeast, magnesium sulfate, potassium dibasic phosphate, cobalt chloride and calcium carbonate, in preferred weight percentages of the fermentation medium, respectively, of: 4.5%, 1.0%, 1.0%, 0.01%, 0.01% and 0.0001%, and 0.2% (volume/volume) of an antifoam agent such as P-2000 (Dow Corning (trademark)).. The pH of this medium is generally adjusted to about 7.0 to about 7.2 prior to autoclaving and inoculation.
Medium C: cerelose, soybean meal, ammonium sulfate, potassium dibasic phosphate, calcium carbonate, NZ a ine YTT (Sheffield (trademark)) and cobalt chloride in preferred weight percentages of the fermentation medium, respectively, of: 2.0%, 3.0%, 0.5%, 0.5%, 0.3%, 0.5% and 0.0005% and 0.2% (volume/volume) of an antifoam agent such as P-2000 (Dow Corning (trademark)) . The pH of this medium is generally adjusted to about 7.0 to about 7.2 prior to autoclaving and inoculation. The produced compound of the formula I can be recovered from the culture medium by conventional means which are commonly used for the recovery of the other known biologically active substances. The compound of the formula I produced is found in the cultured mycelium and filtrate, and accordingly can be isolated and purified from the mycelium and the filtrate. The mycelium can be separated, by filtering or centrifuging the cultured broth. The mycelium can then be extracted with a conventional solvent, such as methanol or acetone, separated and concentrated. Treatment of the concentrate with a conventional resin (e.g., anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (e.g., activated charcoal, silic acid, silica gel, cellulose, florisil, alumina, etc.), crystallization, and recrystallization are then performed to recover the desired compound.
In a preferred method for preparing the compound of the formula I, inoculum is prepared by scraping vegetative cells from slant.s or Roux bottles inoculated with the N927-101 culture. A solid medium suitable for initial growth on slants and Roux bottles is ATCC medium 172 described below:
Figure imgf000018_0001
pH to 7.0 with KOH;
Vegetative cells from slants are used to inoculate either shake flasks or inoculum tanks; or alternatively the inoculu tanks are inoculated from shake flasks. In shake flasks, growth will generally have reached its maximum in 48 to 96 hours whereas in the inoculum tanks growth will usually be at the most favorable period in 72 to 120 hours. A fermenter is inoculated with vegetative broth from the inoculum flasks or tank under completely aseptic conditions and fermented for a period of 72 to 120 hours. Aeration is maintained in the shake flask by agitation on a shaker or in tanks by forcing sterile air through a sparger at the rate of 1/2 to 2 volume of air per volume of broth per minute. The speed of agitation (stirring) depends upon the type of agitator employed; a shake flask is usually run at 150 to 200 cycles, per minute (cpm) and a fermenter at 300 to 1700 revolutions per minute (rpm) . Sterility must be maintained at all times. The temperature is regulated between 24°C and 36°C. Foaming during the fermentation can be controlled with sterile antifoams such as refined soybean oil, or other suitable antifoaming agents added to the makeup or to the fermenter aseptically as needed after inoculation.
Shake flasks are prepared using one of the following media:
Figure imgf000020_0001
Calcium Carbonate pH 7.0 - 7.1
Figure imgf000020_0002
pH to 6.5 - 6.7 One hundred ml of medium is distributed into 300 ml shake flasks and sterilized at 120°C and 1.06 kg/cm2 for 30 minutes. After cooling, the medium is inoculated with a vegetative cell suspension from the N927-101 slant culture grown on ATCC medium 172 in agar. The flasks are shaken at 28°C on a shaker having a displacement of 2.5-3.8 cm to 5.0- -19-
7.3 cm and 150 to 200 rpm for 2 to 4 days. Ten ml may be used to inoculate one 2.8 liter Fernbach flask containing 1 liter of media or 1 flask may be used to inoculate a 5 liter fermentation vessel containing 3 liters of 1 of the following media:
Figure imgf000021_0001
pH to 7.0 - 7.2
One ml of P-2000 is added as an antifoaming agent to the jar fermenters only, then the vessels are sealed and sterilized at 120°C and 1.06 kg/cm2 for 60 to 90 minutes. The jars are inoculated with one (about 3% inoculum) flask, fermented for 72 to 120 hours at 27βC and stirred at 1700 rpm with an air rate of one volume of air per volume of liquid per minute. The shake flasks (Fernbachs) are run at 150 ~ 200 cpm on a shaker at 28°C and fermented for 72 to 120 hours. The fermenters are stopped and the contents extracted twice with one third to one half volume of a solvent such as methyl isobutyl ketone or n-butanol. The solvent layer is separated by aspiration or centrifugation, sparkled, and concentrated in vacuo to a viscous oil.
The bioactivity of the broth and subsequent recovery streams can be followed by HPLC or by using a strain of a filamentous fungi, e.g., Byssochlamys fulva. The components in the broth and recovery streams can also be visualized by chromatography on Analtech silica gel FG (trademark) plates using neat ethyl acetate or chlorofor -methanol 10:1 as the eluant. The developed plates are viewed under ultraviolet light at 254 nm or are sprayed with vanillin reagent (e.g.. 3 g vanillin in 75 ml of ethanol and 25 ml 85% phosphoric acid) and heated to 80°C. The compound appears as a gray blue spot. Extracts of the broth may be run in a Waters (trademark) analytical HPLC using a Zorbax CN (trademark) column and an isocratic system such as H2o-acetonitrile
55:45.
Larger scale fermentations may be carried out by preparing shake flasks containing one liter of compound of formula I inoculum medium. The shake flask inoculum is fermented for 2 to 4 days at 28°C, and then used to inoculate a 50-gallon fermenter containing 25 gallons of production medium. The broth is harvested after running 3 to 5 days.s The whole broth is extracted with 1/3 volume of methyl isobutyl ketone (MIBK) at natural pH, separated on an Alpha De Laval (trademark) separator and the solvent phase concentrated in vacuo to an oil. The term natural pH refers to the pH of the fermentation when stopped, or, if the pH is controlled, the pH at which the fermentation was run or maintained. The oil thus obtained may be processed as described below in Example 1.
Larger fermenters can be staged. A 100-gallon charge of compound of formula I seed medium is inoculated by side arm flask, run approximately 48 hours, then pumped aseptically into 1000 gallons of production medium. The compound of the formula I inhibits the rotamase activity of human FK-binding protein. Functional biological activity in a human mixed lymphocyte reaction (MLR) may be demonstrated by standard procedures well known to those skilled in the art. The immunosuppressant effect of the compound of the formula I may also be demonstrated by the following assay which measures the proliferation of mouse T lymphocytes stimulated with the combination of ionomycin plus PMA (phorbol myristate acetate) . A positive sample in this assay will inhibit T-cell proliferation, as indicated by reduced tritiated thy idine uptake. Assay
Spleens from C57BI/6 mice are taken under sterile conditions and gently dissociated in ice-cold RPMI 1640 (trademark) culture medium (GIBCO (trademark) ) supplemented with 10% heat-inactivated fetal calf serum (GIBCO (trademark) ) . Cells are pelleted by centrifugation at 1500 rpm for 8 minutes. Contaminating red cells are removed by treating the pellet with ammonium chloride lysing buffer (GIBCO (trademark) ) for 2 minutes at 4βC. Cold medium is added and cells are again centrifuged at 1500 rpm for 8 minutes. T lymphocytes are then isolated by separation of the cell suspension on nylon wool columns as follows: Nylon wool columns are prepared by packing approximately 4 grams of washed and dried nylon wool into 20 ml plastic syringes. The columns are sterilized by autoclaving at 120βC for 30 minutes. Nylon wool columns are wetted with warm (37°C) culture medium and rinsed with the same medium. Washed spleen cells resuspended in warm medium are slowly applied to the nylon wool. The columns are then incubated in an upright position at 37°C for 1 hour. Non-adherent T lymphocytes are eluted from the columns with warn culture medium and the cell suspensions are spun as above.
Purified T lymphocytes are resuspended at 106 cells/ml in complete culture medium composed of RPMI 1640 (trademark) medium with 10% heat-inactivated fetal calf serum, 100 mM glutamine, lmM sodium pyruvate, 20 μm 2-mercaptoethanol and 50 μg/ l gentamicin. Ionomycin is added at 250 ng/ml and PMA at 10 ng/ml. The cell suspension is immediately distributed into 96-well flat-bottom microculture plates (Costar (trademark)) at 100 μl/well. Control (cyclosporin) medium or sample to be tested are then added in triplicate wells at 10 μl/well. The culture plates are then incubated at 37βC in a humidified atmosphere of 5% C02-95% air for 44 hours. The proliferation of T lymphocytes is assessed by measurement of tritiated thymidine incorporation. After 44 hours of culturing, the cells are pulse-labelled with 2 Ci/well of tritiated thymidine (New England Nuclear (trademark) ) . After another 4 hours of incubation, cultures are harvested on glass fiber filters using a multiple sample harvester. Radioactivity of filter discs corresponding to individual wells is measured by standard liquid scintillation counting method (Beta plate counter) . Mean counts per minute of replicate wells are calculated and the results expressed as percent inhibition of tritiated thymidine uptake (proliferation) as follows: % Inhibition = 100 - Mean cpm sample tested x 100. Mean cpm control medium
The compound of the formula I has immunosuppressive activity and is therefore useful for the treatment and prevention, of the transplantation rejection of organs or tissues such as heart, kidney, liver, medulla ossium, skin, etc., graft-versus-host diseases by medulla ossium transplantation, autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis and type I diabetes. The compound also has antimicrobial activity and is useful in treating infectious diseases caused by pathogenic filamentus fungal organisms.
The pharmaceutical compositions of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semi-solid or liquid form, which contains a compound of the formula I as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semi-solid, or liquid form, and in -23- addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. For applying such pharmaceutical compositions to a human, it is preferable to apply the compositions by parenteral or oral administration. While the dosage of therapeutically effective amount of the compound of formula I depends upon the age and condition of each individual patient to be treated, a daily dose (calculated on the basis of a 70 kg man) of about 0.01 to about 1000 mg, preferably about 0.1 to about 500 mg and more preferably about 0.5 to about 100 mg of the active ingredient is generally given for treating transplantation rejection or the diseases referred to above, and an average single dose of about 0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg or 500 mg is generally administered. The following examples are given for the purpose of illustrating the present invention and should not be construed as being limitations on its scope.
Example 1 Fermentation of N927-101 The organism N927-101 was isolated from a soil sample collected in Misumitown, Yamaguchi Prefecture, Japan. A. Microtiter Fermentation
A sample of N927-101 colony on an agar-plate was inoculated into a seed medium W (2.5 ml) containing glucose (1 g) , dextrin, polypeptone (5 g/1), yeast extract (5 g/1), beef extract (3 g/1) and CaC03 (4 g/1) in a 24-well microtiter plate and cultured at 28°C for 3 days on a rotary shaker with 7-cm throw at 200 rpm. The seed culture (0.15- 0.3 ml) thus obtained was inoculated to a production medium (3 ml) containing glucose (10 g/1), corn starch (20 (g/1), NZ amine type-A (5 g/1) , yeast extract 5 (g/1) , wheat embryo (5 g/1), COCl2»H20 (0.001 (g/1) and CaC03 (4 g/1) in a 24-well microtiter plate and cultured under the same conditions as the above seed culture except that the fermentation was 4 days.
The fermentation broth thus obtained was applied to a TLC (thin layer chromatography) plate (Kieselgel βOF^, E. Merck (trademark) 20x20 cm) and developed by CHC13: CH3OH (9:1). After the solvent was removed, the TLC plate was placed in a bioplate (28x44 cm) and overlayed by 300 ml of malt yeast agar (malt extract 20 g, yeast extract 4 g, agar 20 g in 1,000 ml) seeded with Byssochlamys fulva. The bioplate was incubated at 28βC for 48 hours. At least two compounds were detected as the inhibition zones against the test organism with Rf values of 0.30 and 0.55. B. Flask Fermentation In order to determine whether the compounds produced by the N927-101 colony where the same as known compounds, flask fermentation was carried out. A seed culture (100 ml) inoculated with 0.5 ml of frozen seed-culture from the microtiter fermentation was fermented as described above and then 5 ml were used to prepare 100 ml of a main culture which was fermented as described above. 150 ml of the resulting fermentation broth was extracted with 100 ml of ethyl acetate (EtOAc) . The EtOAc solution was concentrated to dryness. The residue was dissolved in 2 ml of acetone and submitted to TLC-bioautography. The TLC-bioautography with Byssochlamys fulva indicated that two FK-related compounds were reproduced. One of them having the Rf value of 0.55 was identical to FK-520 based on the HPLC analysis (Zorbax CN, Dupont (trademark) column: 4.6 mm x 25 cm; eluent: 55% water/45% acetonitrile; flow rate: 1 ml/min; detection: UV 214 nm) . Another compound with the Rf value of 0.30 was novel. C. Mini-iar Fermentation
In order to isolate the novel compound and determine the structure, mini-jar fermentation was carried out. A first seed culture was prepared by inoculating 100 ml of medium with 5 ml of frozen seed culture from the shake-flask fermentation. The medium (WGB medium) comprised water, glucose (20 g/1) , polypeptone (5 g/1) , yeast extract (5 g/1), beef extract (3 g/1), wheat gluten (5 g/1), blood meal (3 g/1) , and CaC03 (4 g/1) . The culture was maintained at 28βC for four days with rotation at 200 rpm. Second seed cultures were prepared by inoculating 150 ml of WGB medium with 7.5 ml of the fermented first seed culture. The culture was maintained at 28°C for three days with rotation at 200 rpm and aeration at 1.0 volume/volume/minute.
Main cultures were prepared in five 6-liter mini-jars by inoculating 3 liters of medium in each jar with 150 ml of the second seed culture. The medium (IT-2 medium) comprised glucose (10 g/1) , dextrin (20 g/1) , wheat gluten (10 g/1) , corn steep liquor (5 g/1), polypeptone (1 g/1), (NH4)2S04 (1 g/1), CaC03 (4 g/1) and COC12.6H20 (0.001 g/1).
The whole mini-jar fermentation broth (15 1) was freeze-dried and the solid (397 g) was extracted with two 5- liter portions of 70% aqueous acetone and concentrated to 2.5 1 of aqueous suspension. The suspension was extracted with two 2-liter portions of methyl isobutyl ketone and the combined extract was concentrated to oily residue. A small amount of ether (100 ml) was added to the oily residue to give a precipitate. After collecting the precipitate (2.8 g), the ether solution was concentrated and 100 ml of n-hexane was added to yield 1.7 g of gum-solid. The 2.8 and 1.7 g gum solids were combined and applied to a 120 g fine mesh silica gel column which was developed with 1 L of 3:1 hexanes/ethyl acetate, followed by 1 L of 2:1 hexanes/ethyl acetate, 1 L of 1:1 hexanes/ethyl acetate, 1 L of 2:1 ethyl acetate/hexanes and finally by 2 L of ethyl acetate to yield 25 mg of FK-520 and 125 mg of a mixture of FK-520 and a novel compound. This mixture was applied to a 10 g fine mesh silica gel column which was eluted with 200 ml of chloroform followed by 200 ml of chloroform with 2% ethanol, 200 ml of chloroform with 5% methanol, and finally 100 ml of chloroform with 10% methanol to yield 10 mg of the new compound. This was further purified on a 1 g Clg column developed with methanol and water in a ratio of 4/1 to yield 4 mg of the novel compound later found to have the formula I. Example 2 Large Scale Flask Fermentation Shake flasks containing 80 ml of ATCC 172 medium were inoculated and fermented for 3 to 4 days at 28°C, then 10 ml was used to inoculate a 2.8 liter Fernbach flask containing one liter of ATCC 172 medium. The fermenter, after running 3 to 5 days, was harvested.
47 liters of N927-101 broth was extracted with methyl isobutyl ketone (MIBK) at natural pH. The MIBK phase was separated and concentrated in vacuo to an oil. The oil was defatted using acetonitrile and hexanes to give 4.0 g of a dark viscous liquid. This residue was chromatographed on 128 g of -.fine mesh silica gel which was pre-equilibrated with hexanes and ethyl acetate (1:1). The column was developed with 1 L of 1:1 ethyl acetate/hexanes, followed by 1 L of 2:1 ethyl acetate/hexanes, 1 L of 4:1 ethyl acetate/hexanes and finally by 1.5 L of ethyl acetate to yield 290 mg of a yellow oil. This mixture was then chromatographed on a second fine mesh silica gel column which was pre-equilibrated with chloroform and developed with 200 ml of chloroform, followed by 500 ml of chloroform with 1% methanol and then with 500 ml of chloroform with 2% methanol to yield 125 mg of an oil. This oil was chromatographed on Baker (trademark) Clg bulk packing for flash chromatography using methanol and water (3:1) to give 42 mg of product. Proton NMR and carbon NMR (see Figures 1 and 2) indicated the chemical structure of the product to be as shown in formula I. The molecular weight of 777, as determined by FAB (fast atom bombardment) mass spectroscopy, is consistent with the formula I.

Claims

CLAIMS 1. A process for preparing a compound of the formula
Figure imgf000029_0001
comprising fermenting under aerobic conditions a compound of the formula I producing strain of bacteria in an aqueous medium containing a carbon source and a nitrogen source.
2. A process according to claim 1 comprising fermenting an organism having the characteristics of Streptomyces braeqensis subsp. pulcherrimus Huang subsp. nov., ATCC 55150, or fermenting ATCC 55150, in either case under aerobic conditions in an aqueous medium containing a carbon source and a nitrogen source.
3. A process according to claim 1 or 2, wherein said fermentation is conducted at a pH between about 4.0 and about 8.0.
4. A process according to claim 1 or 2, further comprising recovering said compound of formula I by extracting the fermentation broth with an organic solvent at a pH of about 4.0 to about 8.0.
5. A process according to claim 1 or 2, further comprising recovering said compound of formula I by separating the mycelium and extracting it with an organic solvent at a pH of about 4.0 to about 8.0. -28-
6. A process according to claim 1, wherein said fermentation is conducted at a temperature from about 20°C to about 40°C, for a period of time from about 50 hours to about 150 hours.
7. A process according to claim 9, wherein said fermentation is conducted at a temperature from about 24°C to about 36°C under submerged conditions with agitation and aeration on a medium consisting of a carbon source and a nitrogen source, one or more mineral salts containing trace metals and one or more buffering agents.
8. A biologically pure culture having the characteristics of Streptomyces braeqensis subsp. pu1cherrimus Huang subsp. nov., ATCC 55150, and any mutant or transformant thereof capable of producing the compound of the formula
Figure imgf000030_0002
Figure imgf000030_0001
9. ATCC 55150, a biologically pure culture according o claim 14.
PCT/US1992/002324 1991-04-11 1992-03-27 Novel immunosuppressant agent from streptomyces braegensis WO1992018506A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/129,159 US5494820A (en) 1991-04-11 1992-03-27 Streptomyces braegensis strain and its cultivation in a process for producing C9 -desoxo-FK-520
FI934447A FI934447A0 (en) 1991-04-11 1993-10-08 NOW IMMUNHAEMMANDE AEMNE FRAON STRPTOMYCES BRAEGENSIS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68363991A 1991-04-11 1991-04-11
US683,639 1991-04-11

Publications (1)

Publication Number Publication Date
WO1992018506A1 true WO1992018506A1 (en) 1992-10-29

Family

ID=24744882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/002324 WO1992018506A1 (en) 1991-04-11 1992-03-27 Novel immunosuppressant agent from streptomyces braegensis

Country Status (8)

Country Link
US (1) US5494820A (en)
EP (1) EP0582690A1 (en)
JP (1) JPH06501026A (en)
CA (1) CA2107110C (en)
FI (1) FI934447A0 (en)
IE (1) IE921143A1 (en)
PT (1) PT100365A (en)
WO (1) WO1992018506A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642516A4 (en) * 1991-09-05 1994-06-15 Abbott Lab Macrocyclic immunomodulators.
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
WO2003068980A2 (en) 2002-02-13 2003-08-21 Biogal Gyogyszergyar Rt Method for extracting a macrolide from biomatter
US7220357B2 (en) 2003-07-24 2007-05-22 Teva Gyógyszergyár Zártkörúen Múkó´dó´Résvénytársaság Method of purifying macrolides
US7232486B2 (en) 2003-03-31 2007-06-19 TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság Crystallization and purification of macrolides
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293890B1 (en) * 2018-12-11 2021-08-27 주식회사 몰젠바이오 A novel compound and a composition for promoting hair growth comprising the same
WO2020122611A1 (en) * 2018-12-11 2020-06-18 이화여자대학교 산학협력단 Novel compound and composition comprising same for stimulating hair growth

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323042A1 (en) * 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
EP0402931A1 (en) * 1989-06-14 1990-12-19 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
EP0406791A2 (en) * 1989-07-05 1991-01-09 Fujisawa Pharmaceutical Co., Ltd. Aqueous liquid composition for external use
WO1991002736A1 (en) * 1989-08-18 1991-03-07 Fisons Plc Macrocyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404190A (en) * 1982-01-22 1983-09-13 The Upjohn Company Composition of matter and process
EP0323865A1 (en) * 1988-01-07 1989-07-12 Merck & Co. Inc. Novel immunosuppressant agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0323042A1 (en) * 1987-12-09 1989-07-05 FISONS plc Process to macrocyclic compounds
EP0402931A1 (en) * 1989-06-14 1990-12-19 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
EP0406791A2 (en) * 1989-07-05 1991-01-09 Fujisawa Pharmaceutical Co., Ltd. Aqueous liquid composition for external use
WO1991002736A1 (en) * 1989-08-18 1991-03-07 Fisons Plc Macrocyclic compounds

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642516A4 (en) * 1991-09-05 1994-06-15 Abbott Lab Macrocyclic immunomodulators.
EP0642516A1 (en) * 1991-09-05 1995-03-15 Abbott Laboratories Macrocyclic immunomodulators
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
WO2003068980A2 (en) 2002-02-13 2003-08-21 Biogal Gyogyszergyar Rt Method for extracting a macrolide from biomatter
EP1474404A2 (en) 2002-02-13 2004-11-10 Biogal Gyogyszergyar Rt. Method for extracting a macrolide from biomatter
EP1474404A4 (en) * 2002-02-13 2006-01-11 Biogal Gyogyszergyar Method for extracting a macrolide from biomatter
US7432074B2 (en) 2002-02-13 2008-10-07 TEVA Gyógyszergyár Zártkörüen MüködöRészvénytársaság Method for extracting a macrolide from biomatter
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
US7232486B2 (en) 2003-03-31 2007-06-19 TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság Crystallization and purification of macrolides
US7220357B2 (en) 2003-07-24 2007-05-22 Teva Gyógyszergyár Zártkörúen Múkó´dó´Résvénytársaság Method of purifying macrolides

Also Published As

Publication number Publication date
CA2107110C (en) 1996-02-20
JPH06501026A (en) 1994-01-27
FI934447A (en) 1993-10-08
PT100365A (en) 1993-06-30
US5494820A (en) 1996-02-27
EP0582690A1 (en) 1994-02-16
FI934447A0 (en) 1993-10-08
CA2107110A1 (en) 1992-10-12
IE921143A1 (en) 1992-10-21

Similar Documents

Publication Publication Date Title
KR930010705B1 (en) Tricyclo compound and preparation thereof
EP0627009B1 (en) Macrocyclic lactones and a productive strain thereof
EP0349049A3 (en) Immunosuppressant compound
EP0349061A3 (en) Immunosuppressant agent
US5431896A (en) Microbial immunoregulant
JPH0691816B2 (en) Novel manufacturing method of FK-506
US5494820A (en) Streptomyces braegensis strain and its cultivation in a process for producing C9 -desoxo-FK-520
US4975372A (en) Microbial transformation product of L-683,590
US5221625A (en) Cyclcic FR-900520 microbial biotransformation agent
EP0109750B1 (en) Nargenicin c1
EP0094176B1 (en) Macrolide antibiotics from streptomyces
US4835141A (en) Neutral macrolide antibiotics from Streptomyces
EP0396400A1 (en) Microbial transformation product
US5290689A (en) New cyclic FR-900520 microbial biotransformation agent
US5283183A (en) Cyclic FR-900520 microbial biotransformation agent
US4956283A (en) Process for preparing macrolide antibiotics by culturing streptomyces hirsutus ATCC 53513
EP0478235A2 (en) A directed biosynthesis for an immunomycin derivative
US4450237A (en) Streptomyces albus subspecies indicus
US5268281A (en) Cyclic FR-900520 microbial biotransformation agent
US5268282A (en) Cyclic FR-900520 microbial biotransformation agent
EP0378317A2 (en) Microbial transformation product of L-679,934
EP0520554A2 (en) C-21 hydroxylated FK-506 antagonist
EP0378320A2 (en) Microbial transformation product
GB2266307A (en) Microbial transformation product of L-679,934

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA FI JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992922771

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2107110

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 934447

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 08129159

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1992922771

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992922771

Country of ref document: EP